Abstract:The metabolism and catabolism of sphingolipids is a clinically important pathway in which multiple conditions have been described, including Metachromatic Leukodystrophy, Tay-Sachs disease, Fabry disease, Niemann-Pick disease, and Krabbe disease, among others. The biosynthesis of ceramide, a key component of sphingolipids, is also recognized as a clinically significant pathway, particularly in neurological disease. Among these, Hypomyelinating Leukodystrophy due to variants in DEGS1 (MIM 615843) is a newly described condition. DEGS1 encodes delta-4-dihydroceramide desaturase (DEGS1) which catalyzes dihydroceramide into ceramide and is a key component of the de novo ceramide biosynthesis pathway. Clinical features associated with this condition include early onset progressive hypomyelinating leukodystrophy, global developmental delays, dystonia, spasticity, nystagmus, feeding difficulties, and poor survival. The cellular effects of DEGS1 deficiency include accumulation of dihydroceramides leading to activation of the Rac1-NADPH oxidase (NOX) pathway, abnormal regulation of amino acid transporters, and abnormal regulation of related sphingomyelin species and their regulatory roles within an intricate metabolic network. Inhibition of the NOX pathway in DEGS1 deficient cells and mice has been demonstrated to reduce neuronal oxidative stress, supporting the possible use of NOX inhibitors to prevent neurodegeneration, and treatment with fingolimod, a drug targeting sphingosine-1-phosphate signaling, reduced dihydroceramide accumulation in DEGS1 knockout mice with phenotypic improvement. Despite this, care for patients with this condition is currently supportive and no validated, noninvasive biomarkers have been identified to facilitate clinical trials for DEGS1 deficiency. Our case presents an analysis of the ceramide pathway and the global metabolic perturbations in an individual with this disorder and paves the way for future biomarker discovery to aid in clinical trial readiness. This case also highlights the power of paired molecular and metabolomic profiling to provide a precise diagnosis after a years-long diagnostic odyssey. We present a case of an 8 yo male with a history of intractable epilepsy, microcephaly, spastic quadriparesis, feeding difficulties, cortical visual impairment, frequent fractures, and sensorineural hearing loss. Brain MRIs revealed diffuse progressive leukodystrophy in the bilateral cerebral hemispheres, cerebral volume loss, and subtle lactate peak on spectroscopy. Exome sequencing revealed a novel homozygous variant, NM_003676.3 c.775C>T p.His259Tyr, in DEGS1. This variant has not previously been described, is absent from population controls, and located in a histidine box functional domain. To assess for perturbations in biochemical pathways due to DEGS1 deficiency, we performed untargeted metabolomic profiling in plasma, which revealed numerous biochemical abnormalities in sphingolipid metabolism, purine biosynthesis, and amino acid metabolism. Typical ceramide species (ceramide, hexosylceramides, and lactosylceramides) were absent, and downstream sphingomyelins were either absent or dramatically decreased and among the lowest levels observed in our clinical database. Further, sphingosine and sphingosine 1 phosphate, components of the ceramide salvage pathway, were absent and significantly reduced, respectively. Significant elevations of upstream substrates for DEGS1, including sphinganine-1-phosphate, multiple dihydroceramides, and dihydrosphingomyelins were observed, in addition to altered catecholamines and multiple abnormalities in amino acid metabolism. Taken together, these findings are consistent with deficiency of DEGS1 and confirm the diagnosis of DEGS1 Hypomyelinating Leukodystrophy in our patient. We present a case of an individual with a novel genetic finding in the de novo ceramide biosynthesis pathway, DEGS1, for whom biochemical characterization was able to provide a precise genetic diagnosis. This case highlights the potential of clinical metabolomic pathway screening in the diagnosis and evaluation of individuals with sphingolipidoses and related conditions. Several target therapeutic mechanisms have been proposed for this disease including substrate reduction and inhibiting NOX pathway activity. Validation and further characterization of analytes in this pathway for DEGS1 and other sphingolipidoses is an important step in clinical trial readiness for this newly described condition. Pathway screening for other individuals identified with DEGS1 variants within our Leukodystrophy Center and care network is ongoing.

A pathway revisited

A pseudoautosomal glycosylation disorder prompts the revision of dolichol biosynthesis

N-glycoproteomic and proteomic alterations in SRD5A3-deficient fibroblasts

A case of fatal Type I congenital disorders of glycosylation (CDG I) associated with low dehydrodolichol diphosphate synthase (DHDDS) activity

The N-glycosylation defect in Lec5 and Lec9 CHO cells is caused by absence of the DHRSX gene

Absence of the dolichol synthesis gene DHRSX leads to N-glycosylation defects in Lec5 and Lec9 Chinese hamster ovary cells

Modeling Congenital Disorders of N-Linked Glycoprotein Glycosylation in Drosophila melanogaster

N-Glycosylation Defects in Humans Lower Low-Density Lipoprotein Cholesterol Through Increased Low-Density Lipoprotein Receptor Expression

Prospective phenotyping of NGLY1-CDDG, the first congenital disorder of deglycosylation

A drug repurposing screen reveals dopamine signaling as a critical pathway underlying potential therapeutics for the rare disease DPAGT1-CDG

Inherited Retinal Degeneration Caused by Dehydrodolichyl Diphosphate Synthase Mutation–Effect of an ALG6 Modifier Variant

Sugary Logistics Gone Wrong: Membrane Trafficking and Congenital Disorders of Glycosylation

(Key1-001) congenital disorders of glycosylation: Glycobiology at the bedside

Ep176: Metabolomics Reveals Measurable Perturbations in De Novo Ceramide Biosynthesis in DEGS1 Associated-Hypomyelinating Leukodystrophy - Towards a Clinically Significant Biomarker Profile

Revisiting the immunopathology of congenital disorders of glycosylation: an updated review

Doubling of Optic Disc

COG8 Deficiency Causes New Congenital Disorder of Glycosylation Type IIh

Deficient glycan extension and endoplasmic reticulum stresses in ALG3‐CDG

Evolutionary rate covariation is pervasive between glycosylation pathways and points to potential disease modifiers

Loss of function and reduced levels of sphingolipid desaturase DEGS1 variants are both relevant in disease mechanism.

COG7 deficiency in Drosophila generates multifaceted developmental, behavioral and protein glycosylation phenotypes